Health Care·Biotechnology·$28.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.82 | N/A | +5.53% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.82 | N/A | +5.53% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a commitment to their clinical programs while acknowledging current challenges. They did not provide specific guidance for the future.
We are focused on advancing our clinical programs despite the challenging environment.
Our team remains committed to our strategic goals.
Revolution Medicines reported a wider-than-expected loss per share, which slightly exceeded analyst expectations. However, the lack of revenue data and guidance contributed to a negative stock reaction, with shares falling 2.62%. Investors may be concerned about the company's future direction given the absence of specific guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DOMINION ENERGY INC
Aug 8, 2022